Unicycive Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:UNCY) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -5.77 M-15.65 M-18.28 M-28.57 M-31.32 M -27.84 M Cash from investing activities -29 K-2 000-12 K-72 K-12.1 M -17.25 M Cash from financing activities 22.38 M-471 K27.54 M45.09 M46.47 M 66.95 M Free cash flow -5.77 M-15.65 M-18.28 M-28.57 M-31.32 M -27.84 M

News

Unicycive Therapeutics: Two CRLs, One Fixable Problem (NASDAQ:UNCY)

Unicycive Therapeutics: Second CRL Exposes Execution Risk Behind OLC Story (NASDAQ:UNCY)

Stock Picks From Seeking Alpha's May 2026 New Analysts

Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside

Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript

Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile

FDA sets June 27 review date for Unicycive’s kidney drug

Unicycive stock rises after FDA accepts OLC drug application resubmission

Guggenheim reiterates Buy rating on Unicycive stock amid NDA resubmission

Unicycive resubmits NDA for kidney disease treatment to FDA

Piper Sandler highlights commercial biotech names to own in 2026

Unicycive stock price target lowered to $63 by Lucid Capital Markets